The paradoxical patterns of expression of indoleamine 2,3-dioxygenase in colon cancer.
BACKGROUND
One of the putative mechanisms of tumor immune escape is based on the hypothesis that carcinomas actively create an immunosuppressed state via the expression of indoleamine 2,3-dioxygenase (IDO), both in the cancer cells and in the immune cells among the tumor-draining lymph nodes (TDLN). In an attempt to verify this hypothesis, the patterns of expression of IDO in the cancer cells and the immune cells among colon cancers were examined.


METHODS
Seventy-one cases of pathologically-confirmed colon cancer tissues matched with adjacent non-cancerous tissues, lymph node metastases, and TDLN without metastases were collected at the Sun Yat-sen Cancer Center between January 2000 and December 2000. The expression of IDO and Bin1, an IDO regulator, was determined with an immunohistochemical assay. The association between IDO or Bin1 expression and TNM stages and the 5-year survival rate in colon cancer patients was analyzed.


RESULTS
IDO and Bin1 were detected in the cytoplasm of cancer cells and normal epithelium. In primary colon cancer, the strong expression of IDO existed in 9/71 cases (12.7%), while the strong expression of Bin1 existed in 33/71 cases (46.5%). However, similar staining of IDO and Bin1 existed in the adjacent non-cancerous tissues. Among the 41 cases with primary colon tumor and lymph node metastases, decreased expression of IDO was documented in the lymph node metastases. Furthermore, among the TDLN without metastases, a higher density of IDO+cells was documented in 21/60 cases (35%). Both univariate and multivariate analyses revealed that the density of IDO+cells in TDLN was an independent prognostic factor. The patients with a higher density of IDO+cells in TDLN had a lower 5-year survival rate (37.5%) than the cells with a lower density (73.1%).


CONCLUSIONS
This study demonstrated paradoxical patterns of expression of IDO in colon cancer. The high density IDO+cells existed in TDLN and IDO was down-regulated in lymph nodes with metastases, implying that IDO in tumor and immune cells functions differently.
Gao
Yan-Fang
YF
State Key Laboratory of Oncology in South China, 651 Dongfeng R E, 510060, Guangzhou, PR China. gyf814@tom.com
Peng
Rui-Qing
RQ
Li
Jiang
J
Ding
Ya
Y
Zhang
Xing
X
Wu
Xiao-Jun
XJ
Pan
Zhi-Zhong
ZZ
Wan
De-Sen
DS
Zeng
Yi-Xin
YX
Zhang
Xiao-Shi
XS
D048868:Adaptor Proteins, Signal Transducing / Q000235:genetics / Q000378:metabolism; D003110:Colonic Neoplasms / Q000201:enzymology* / Q000235:genetics / Q000276:immunology / Q000473:pathology; D005260:Female; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase / Q000235:genetics / Q000378:metabolism*; D008198:Lymph Nodes / Q000166:cytology / Q000201:enzymology / Q000276:immunology / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009687:Nuclear Proteins / Q000235:genetics / Q000378:metabolism; D015996:Survival Rate; D025521:Tumor Suppressor Proteins / Q000235:genetics / Q000378:metabolism
D048868:Adaptor Proteins, Signal Transducing; C101410:BIN1 protein, human; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase; D009687:Nuclear Proteins; D025521:Tumor Suppressor Proteins
Clin Cancer Res. 2008 Nov 15;14(22):7251-9
19010841
Oncogene. 2008 Jun 26;27(28):3889-900
18317452
Cancer Biol Ther. 2007 Aug;6(8):1258-62
17700060
Cancer Immunol Immunother. 2009 Sep;58(9):1363-73
19172271
J Transl Med. 2008 Apr 22;6:19
18430198
Clin Cancer Res. 2008 Feb 1;14(3):654-9
18245524
J Am Coll Surg. 2008 May;206(5):849-54; discussion 854-6
18471709
Curr Opin Immunol. 2006 Apr;18(2):220-5
16460921
J Clin Invest. 2004 Jul;114(2):270-9
15254594
Immunol Rev. 2006 Oct;213:131-45
16972901
Trends Immunol. 2006 Feb;27(2):68-73
16406698
J Clin Invest. 2007 May;117(5):1147-54
17476344
Immunol Rev. 2006 Oct;213:146-58
16972902
J Transl Med. 2008 Oct 30;6:63
18973649
Int J Cancer. 1995 Jan 3;60(1):115-22
7814143
Diabetes. 2002 Feb;51(2):356-65
11812742
Nat Med. 2005 Mar;11(3):312-9
15711557
J Immunol. 2006 Oct 15;177(8):5639-46
17015752
Clin Cancer Res. 2009 Jan 15;15(2):641-9
19147770
J Transl Med. 2005 Apr 29;3(1):18
15862126
J Transl Med. 2005 Jan 28;3(1):5
15679891
Mol Cancer Ther. 2008 Dec;7(12):3859-66
19074858
Oncol Rep. 2007 Jun;17(6):1333-9
17487387
J Neurosurg. 2009 Aug;111(2):230-7
19199463
J Clin Invest. 2007 Sep;117(9):2570-82
17710230
Immunol Lett. 2007 Aug 15;111(2):69-75
17644189
Blood. 2006 Jul 1;108(1):228-37
16522817
J Cancer Res Clin Oncol. 2008 Nov;134(11):1247-53
18438685
Handb Exp Pharmacol. 2009;(188):165-96
19031026
Clin Cancer Res. 2006 Feb 15;12(4):1144-51
16489067
Curr Drug Metab. 2007 Apr;8(3):209-16
17430109
J Cancer Res Clin Oncol. 2008 May;134(5):525-33
17909857
Curr Drug Metab. 2007 Apr;8(3):237-44
17430112
Br J Cancer. 2007 Jun 18;96(12):1879-87
17565341
J Transl Med. 2008 Jul 22;6:37
18644158
J Clin Invest. 2004 Jul;114(2):280-90
15254595
Lancet. 2000 Dec 9;356(9246):1981-2
11130529
Int J Biochem Cell Biol. 2007;39(12):2167-72
17320464
Adv Exp Med Biol. 2003;527:91-5
15206720
J Transl Med. 2007 Nov 29;5:62
18047662
J Cell Physiol. 2007 Oct;213(1):137-43
17477384
Langenbecks Arch Surg. 2008 Nov;393(6):995-1003
18064486
Nat Rev Cancer. 2009 Jun;9(6):445-52
19461669
Cancer Res. 2007 Jan 15;67(2):792-801
17234791
Nat Rev Immunol. 2006 Apr;6(4):295-307
16557261
Biochim Biophys Acta. 2004 Feb 10;1661(1):106-12
14967480
Nat Rev Immunol. 2004 Oct;4(10):762-74
15459668
Br J Cancer. 2006 Dec 4;95(11):1555-61
17117179
Biochem Biophys Res Commun. 2005 Dec 9;338(1):12-9
16176799
Science. 1998 Aug 21;281(5380):1191-3
9712583
J Immunol. 2008 Sep 1;181(5):3291-300
18714001
Exp Eye Res. 2007 Nov;85(5):617-25
17870068
J Transl Med. 2003 Sep 19;1(1):5
14572312
Clin Cancer Res. 2007 Dec 1;13(23):6993-7002
18056175
Nat Med. 2003 Oct;9(10):1269-74
14502282
Clin Cancer Res. 2008 Apr 15;14(8):2310-7
18413819